Collagen-binding peptide reverses bone loss in a mouse model of cerebral palsy based on clinical databases

Yoon Kyum Shin, Jeong Hyun Heo, Jue Yeon Lee, Yoon Jeong Park, Sung Rae Cho

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)


Background: Individuals with cerebral palsy (CP) experience bone loss due to impaired weight bearing. Despite serious complications, there is no standard medication. Objective: To develop a new pharmacological agent, we performed a series of studies. The primary aim was to develop an animal model of CP to use our target medication based on transcriptome analysis of individuals with CP. The secondary aim was to show the therapeutic capability of collagen-binding peptide (CBP) in reversing bone loss in the CP mouse model. Methods: A total of 119 people with CP and 13 healthy adults participated in the study and 140 mice were used for the behavioral analysis and discovery of therapeutic effects in the preclinical study. The mouse model of CP was induced by hypoxic-ischemic brain injury. Inclusion and exclusion criteria were established for CBP medication in the CP mouse model with bone loss. Results: On the basis of clinical outcomes showing insufficient mechanical loading from non-ambulatory function and that underweight mainly affects bone loss in adults with CP, we developed a mouse model of CP with bone loss. Injury severity and body weight mainly affected bone loss in the CP mouse model. Transcriptome analysis showed SPP1 expression downregulated in adults with CP who showed lower bone density than healthy controls. Therefore, a synthesized CBP was administered to the mouse model. Trabecular thickness, total collagen and bone turnover activity increased with CBP treatment as compared with the saline control. Immunohistochemistry showed increased immunoreactivity of runt-related transcription factor 2 and osteocalcin, so the CBP participated in osteoblast differentiation. Conclusions: This study can provide a scientific basis for a promising translational approach for developing new anabolic CBP medication to treat bone loss in individuals with CP.

Original languageEnglish
Article number101445
JournalAnnals of Physical and Rehabilitation Medicine
Issue number3
Publication statusPublished - 2021 May

Bibliographical note

Publisher Copyright:
© 2020 The Authors

All Science Journal Classification (ASJC) codes

  • Orthopedics and Sports Medicine
  • Rehabilitation


Dive into the research topics of 'Collagen-binding peptide reverses bone loss in a mouse model of cerebral palsy based on clinical databases'. Together they form a unique fingerprint.

Cite this